Evidence map›Paper›PMID 27980454›Full record

ArticleCancer cell international2016

Comprehensive analysis of the long noncoding RNA HOXA11-AS gene interaction regulatory network in NSCLC cells.

Yu Zhang, Rong-Quan He, Yi-Wu Dang, Xiu-Ling Zhang, Xiao Wang, Su-Ning Huang, Wen-Ting Huang, Meng-Tong Jiang, Xiao-Ning Gan, You Xie and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Expression of microRNA-99a-3p in Prostate Cancer Based on Bioinformatics Data and Meta-Analysis of a Literature Review of 965 Cases.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Expression and Purification of Recombinant ADAMTS8.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Yu Zhang *Department of Pathology, First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021 People's Republic of China.
Rong-Quan He *Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021 People's Republic of China.
Yi-Wu DangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021 People's Republic of China.
Xiu-Ling ZhangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021 People's Republic of China.
Xiao WangDepartment of Orthopedics, China-Japan Union Hospital of Jilin University, 2 Sendai Street, Changchun, 130033 People's Republic of China.
Su-Ning HuangDepartment of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021 People's Republic of China.
Wen-Ting HuangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021 People's Republic of China.
Meng-Tong JiangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021 People's Republic of China.
Xiao-Ning GanDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021 People's Republic of China.
You XieDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021 People's Republic of China.
Ping LiDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021 People's Republic of China.
Dian-Zhong LuoDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021 People's Republic of China.
Gang Chen *Department of Pathology, First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021 People's Republic of China.
Ting-Qing Gan *Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021 People's Republic of China.
Guangxi Medical University · CNFirst Affiliated Hospital of GuangXi Medical University · CNUnion Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong noncoding RNAs (lncRNAs) are related to different biological processes in non-small cell lung cancer (NSCLC). However, the possible molecular mechanisms underlying the effects of the long noncoding RNA HOXA11-AS (HOXA11 antisense RNA) in NSCLC are unknown.

methodsHOXA11-AS was knocked down in the NSCLC A549 cell line and a high throughput microarray assay was applied to detect changes in the gene profiles of the A549 cells. Bioinformatics analyses (gene ontology (GO), pathway, Kyoto Encyclopedia of Genes and Genomes (KEGG), and network analyses) were performed to investigate the potential pathways and networks of the differentially expressed genes. The molecular signatures database (MSigDB) was used to display the expression profiles of these differentially expressed genes. Furthermore, the relationships between the HOXA11-AS, de-regulated genes and clinical NSCLC parameters were verified by using NSCLC patient information from The Cancer Genome Atlas (TCGA) database. In addition, the relationship between HOXA11-AS expression and clinical diagnostic value was analyzed by receiver operating characteristic (ROC) curve.

resultsAmong the differentially expressed genes, 277 and 80 genes were upregulated and downregulated in NSCLC, respectively (fold change ≥2.0, P < 0.05 and false discovery rate (FDR) < 0.05). According to the degree of the fold change, six upregulated and three downregulated genes were selected for further investigation. Only four genes (RSPO3, ADAMTS8, DMBT1, and DOCK8) were reported to be related with the development or progression of NSCLC based on a PubMed search. Among all possible pathways, three pathways (the PI3K-Akt, TGF-beta and Hippo signaling pathways) were the most likely to be involved in NSCLC development and progression. Furthermore, we found that HOXA11-AS was highly expressed in both lung adenocarcinoma and squamous cell carcinoma based on TCGA database. The ROC curve showed that the area under curve (AUC) of HOXA11-AS was 0.727 (95% CI 0.663-0.790) for lung adenocarcinoma and 0.933 (95% CI 0.906-0.960) for squamous cell carcinoma patients. Additionally, the original data from TCGA verified that ADAMTS8, DMBT1 and DOCK8 were downregulated in both lung adenocarcinoma and squamous cell carcinoma, whereas RSPO3 expression was upregulated in lung adenocarcinoma and downregulated in lung squamous cell carcinoma. For the other five genes (STMN2, SPINK6, TUSC3, LOC100128054, and C8orf22), we found that STMN2, TUSC3 and C8orf22 were upregulated in squamous cell carcinoma and that STMN2 and USC3 were upregulated in lung adenocarcinoma. Furthermore, we compared the correlation between HOXA11-AS and de-regulated genes in NSCLC based on TCGA. The results showed that the HOXA11-AS expression was negatively correlated with DOCK8 in squamous cell carcinoma (r = -0.124, P = 0.048) and lung adenocarcinoma (r = -0.176, P = 0.005). In addition, RSPO3, ADAMTS8 and DOCK8 were related to overall survival and disease-free survival (all P < 0.05) of lung adenocarcinoma patients in TCGA.

conclusionsOur results showed that the gene profiles were significantly changed after HOXA11-AS knock-down in NSCLC cells. We speculated that HOXA11-AS may play an important role in NSCLC development and progression by regulating the expression of various pathways and genes, especially DOCK8 and TGF-beta pathway. However, the exact mechanism should be verified by functional experiments.

Indexed as

GOHOXA11-ASKEGGMicroarray assayNSCLCPathway

Identifiers

PMID27980454
PMCPMC5133743
OpenAlexW2558991789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.